Franz M.N.H. Schramel

Author

Also Known As

E Smit, F M N H Schramel, F M Schramel, F Schramel, F. M. N. H. Schramel, F. M. N.H. Schramel, F. M. Schramel, F. M.N.H. Schramel, F. Schramel, F.M Schramel

147

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

St. Antonius Ziekenhuis University Medical Center Utrecht University of Amsterdam The Netherlands Cancer Institute Amsterdam UMC Location Vrije Universiteit Amsterdam

About

Franz M.N.H. Schramel is an author at St. Antonius Ziekenhuis specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	25	1.2K
2	Health Sciences	8	8	524
3	Engineering	1	1	73
4	Anatomy	1	1	69
5	Anesthesia	1	1	42

Franz M.N.H. Schramel

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer Jan P. van Meerbeeck, G. Kramer, Paul Van Schil, JNCI Journal of the National Cancer Institute	2007	707
Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975 Egbert F. Smit, J.P.A.M van Meerbeeck, P. Lianes, Journal of Clinical Oncology	2003	351
Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975 Fabio Efficace, Andrew Bottomley, Egbert F. Smit, Annals of Oncology Quality Of LifeLife AssessmentSelf-reported Health-related QualityMedicineCancer Management	2006	182
Gemcitabine and Cisplatin as Induction Regimen for Patients With Biopsy-Proven Stage IIIA N2 Non–Small-Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955) Nico van Zandwijk, Egbert F. Smit, G. Kramer, Journal of Clinical Oncology	2000	147
Defining a standard set of patient-centred outcomes for lung cancer Kimberley S. Mak, A.C.M. van Bommel, Caleb Stowell, European Respiratory Journal Palliative CareAdvanced Lung DiseaseMedicineCancer ManagementCase-mix Variables	2016	112
Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With Advanced Non–Small-Cell Lung Cancer: The NVALT-4 Study Harry J.M. Groen, Hannie Sietsma, Andrew Vincent, Journal of Clinical Oncology	2011	107
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands Christine M. Cramer‐van der Welle, Marjon V. Verschueren, Merel Tonn, Scientific Reports	2021	103
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study Wieneke A. Buikhuisen, Jacobus A. Burgers, Andrew Vincent, The Lancet Oncology Nvalt 5Surgical OncologyMedicineCancer ManagementActive Supportive Care	2013	97
Fibreoptic bronchoscopic electrosurgery under local anaesthesia for rapid palliation in patients with central airway malignancies: a preliminary report. G. Sutedja, Klaas van Kralingen, Franz M.N.H. Schramel, Thorax	1994	96
Videothoracoscopic Appearance of First and Recurrent Pneumothorax J. Janssen, Franz M.N.H. Schramel, Thomas G. Sutedja, CHEST Journal PneumothoraxRecurrent PneumothoraxPleural EffusionPleural DiseaseThoracic Surgery	1995	93

Page 1